A practical reference on lipogenesis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-01 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
In February 2024, Senator Scott Wiener introduced the Safe and Secure Innovation for Frontier Artificial Intelligence Models Act to the California legislature. The bill drew heavily on the Biden executive order and had the goal of reducing catastrophic risks by mandating safety tests for the most powerful AI models. If passed, the bill would have established a publicly-funded cloud computing cluster in California. Governor Gavin Newsom vetoed the bill in September 2024. The Artificial Intelligence Training Data Transparency Act (AB 2013) and Transparency in Frontier Artificial Intelligence Act (TFAIA) (SB 53) went into effect on January 1, 2026. In addition, the California AI Transparency Act will go into effect in August 2026. By signing TFAIA into law in September 2025, California became the first state to enact a statute specifically addressing the development of frontier AI models. The TFAIA protects whistleblowers who have reasonable cause to believe their employers are endangering lives or causing damages worth $1 billion. It also requires companies to publish their safety test results. The political action committee Parents & Kids Safe AI Coalition, funded by OpenAI, has been involved in efforts to establish legislation related to child safety and AI in California. In September 2024, Alameda County's Board of Supervisors approved a countywide policy for agency and department usage of generative artificial intelligence (GenAI) technology.
== Further reading == Virtual Textbook of Organic Chemistry Visualizations of the low-temperature crystal structures of alkanes (methane to nonane) Redwood, Boverton (1911). "Paraffin" . Encyclopædia Britannica. Vol. 20 (11th ed.). pp. 752–756.
M = the length of a number of links measured S = the number of links measured P = Pitch In industry, it is usual to monitor the movement of the chain tensioner (whether manual or automatic) or the exact length of a drive chain (one rule of thumb is to replace a roller chain which has elongated 3% on an adjustable drive or 1.5% on a fixed-center drive). A simpler method, particularly suitable for the cycle or motorcycle user, is to attempt to pull the chain away from the larger of the two sprockets, whilst ensuring the chain is taut. Any significant movement (e.g. making it possible to see through a gap) probably indicates a chain worn up to and beyond the limit. Sprocket damage will result if the problem is ignored. Sprocket wear cancels this effect, and may mask chain wear.
Other winemakers may allow the wild yeasts to continue fermenting until they succumb to the toxicity of the alcohol they produce which is often between 3–5% alcohol by volume and then letting either inoculated or "ambient" Saccharomyces strains finish the fermentation.
Sources: en.wikipedia.org
proteinogenic amino acid Any of the 20 canonical amino acids which are encoded by the standard genetic code and incorporated into peptides and ultimately proteins during translation. The term may also be inclusive of an additional two amino acids encoded by non-standard codes which can be incorporated by special translation mechanisms.
Based on the MHD equations, Glatzmaier and Paul Roberts developed a supercomputer model of the Earth's interior. After the simulations are run for thousands of years in virtual time, changes in Earth's magnetic field can be studied. The simulation results are in good agreement with observations because the simulations correctly predict that the Earth's magnetic field reverses every few hundred thousand years. During these reversals, the magnetic field does not vanish altogether; instead, it becomes more complex.
Russia claimed to have taken the village of Shumy, ten kilometers east of Toretsk. Seven people were killed and 36 others were injured in a Russian attack in Vilniansk, Zaporizhzhia Oblast. Three people were killed in separate attacks in Donetsk and Kherson Oblasts. Russian officials claimed that five people, including two children, were killed in a Ukrainian drone strike in Gorodishche, Kursk Oblast.
=== Cell Biology and Virology === Organised into subprograms including Eukaryotic Microbiology, Tumor Cell Biology, Virology, and Mammalian Cell Structure/Differentiation, this program studies cellular functions across organisms. Research areas include tumor-virus associations, host-pathogen signaling, gene therapy, and vaccine development.
== Side effects == The most common side effects associated with famotidine use include headache, dizziness, and constipation or diarrhea. Famotidine may contribute to QT prolongation, particularly when used with other QT-elongating drugs, or in people with poor kidney function.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.